Detailed answers about HEMOLENS DIAGNOSTICS LIMITED, including incorporation, status, business activity, and accounts information.
When was HEMOLENS DIAGNOSTICS LIMITED founded?
HEMOLENS DIAGNOSTICS LIMITED was officially incorporated on 28 May 2025 and is registered under company number 16478597. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
What type of company is HEMOLENS DIAGNOSTICS LIMITED?
Private Limited Company. This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations. A private limited company (Ltd) limits the personal liability of its shareholders.
What is the current status of HEMOLENS DIAGNOSTICS LIMITED?
HEMOLENS DIAGNOSTICS LIMITED's current status is Active. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
What does HEMOLENS DIAGNOSTICS LIMITED do?
HEMOLENS DIAGNOSTICS LIMITED operates in the following sectors: 32500 - Manufacture of medical and dental instruments and supplies, 62020 - Information technology consultancy activities, 63110 - Data processing, hosting and related activities, 72190 - Other research and experimental development on natural sciences and engineering. These SIC codes provide insight into the company's business activities and industry focus.
What is HEMOLENS DIAGNOSTICS LIMITED's registered address?
The registered office address of HEMOLENS DIAGNOSTICS LIMITED is EALING CROSS, 1ST FLOOR, 85 UXBRIDGE ROAD, LONDON, UNITED KINGDOM, W5 5TH. This is the official address filed with Companies House for legal and statutory correspondence.
Is HEMOLENS DIAGNOSTICS LIMITED financially stable?
Financial accounts for HEMOLENS DIAGNOSTICS LIMITED are not currently available. Without filed accounts, it is more difficult to assess the company's financial stability and trading performance.